Celgene (CELG) option implied volatility flat; Bristol-Myers (BMY) to acquire
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Oil prices jump 4% as fresh US-Iran fighting stokes supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Dell again lifts forecasts as AI demand powers record results
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
Leerink Partners Downgrades Celgene (CELG) to Market Perform Following Acquisition
January 3, 2019 11:56 AM ESTLeerink Partners analyst Geoffrey Porges downgraded Celgene (NASDAQ: CELG) from Outperform to Market Perform with a price target of $102.00 (from $112.00) following acquisition.
For an analyst ratings summary and ratings history on Celgene click here. For more ratings news on Celgene click here.
Shares of Celgene closed at $66.64 yesterday.
... More